174 related articles for article (PubMed ID: 22688732)
1. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.
Evans JJ; Crist HS; Durvesh S; Bruggeman RD; Goldenberg D
Cancer Biol Ther; 2012 Jul; 13(9):776-81. PubMed ID: 22688732
[TBL] [Abstract][Full Text] [Related]
2. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
3. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression.
Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R
Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome.
Yun JY; Kim YA; Choe JY; Min H; Lee KS; Jung Y; Oh S; Kim JE
J Clin Pathol; 2014 Feb; 67(2):125-33. PubMed ID: 23986551
[TBL] [Abstract][Full Text] [Related]
5. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.
Lam KY; Lo CY; Chan KW; Wan KY
Ann Surg; 2000 Mar; 231(3):329-38. PubMed ID: 10714625
[TBL] [Abstract][Full Text] [Related]
6. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
7. Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines.
Musso R; Di Cara G; Albanese NN; Marabeti MR; Cancemi P; Martini D; Orsini E; Giordano C; Pucci-Minafra I
J Proteomics; 2013 Sep; 90():115-25. PubMed ID: 23385357
[TBL] [Abstract][Full Text] [Related]
8. Expression of leptin and its receptor in thyroid carcinoma: distinctive prognostic significance in different subtypes.
Fan YL; Li XQ
Clin Endocrinol (Oxf); 2015 Aug; 83(2):261-7. PubMed ID: 25158596
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Metabolism as a Treatment Target in Anaplastic Thyroid Cancer.
Johnson JM; Lai SY; Cotzia P; Cognetti D; Luginbuhl A; Pribitkin EA; Zhan T; Mollaee M; Domingo-Vidal M; Chen Y; Campling B; Bar-Ad V; Birbe R; Tuluc M; Martinez Outschoorn U; Curry J
Semin Oncol; 2015 Dec; 42(6):915-22. PubMed ID: 26615136
[TBL] [Abstract][Full Text] [Related]
10. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
12. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
13. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch.
Hébrant A; Dom G; Dewaele M; Andry G; Trésallet C; Leteurtre E; Dumont JE; Maenhaut C
PLoS One; 2012; 7(10):e37807. PubMed ID: 23115614
[TBL] [Abstract][Full Text] [Related]
14. Interactions of Vascular Endothelial Growth Factor and p53 with miR-195 in Thyroid Carcinoma: Possible Therapeutic Targets in Aggressive Thyroid Cancers.
Maroof H; Irani S; Arianna A; Vider J; Gopalan V; Lam AK
Curr Cancer Drug Targets; 2019; 19(7):561-570. PubMed ID: 29956628
[TBL] [Abstract][Full Text] [Related]
15. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma.
Wiseman SM; Griffith OL; Deen S; Rajput A; Masoudi H; Gilks B; Goldstein L; Gown A; Jones SJ
Arch Surg; 2007 Aug; 142(8):717-27; discussion 727-9. PubMed ID: 17709725
[TBL] [Abstract][Full Text] [Related]
16. HN1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by interacting with STMN1.
Pan Z; Fang Q; Li L; Zhang Y; Xu T; Liu Y; Zheng X; Tan Z; Huang P; Ge M
Cancer Lett; 2021 Mar; 501():31-42. PubMed ID: 33359451
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of oncoprotein expressions in thyroid papillary carcinoma.
Balta AZ; Filiz AI; Kurt Y; Sucullu I; Yucel E; Akin ML
Med Oncol; 2012 Jun; 29(2):734-41. PubMed ID: 21547408
[TBL] [Abstract][Full Text] [Related]
18. Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases.
Cameselle-Teijeiro JM; Rodríguez-Pérez I; Celestino R; Eloy C; Piso-Neira M; Abdulkader-Nallib I; Soares P; Sobrinho-Simões M
Am J Surg Pathol; 2017 Jun; 41(6):854-860. PubMed ID: 28009606
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma.
Shin MK; Kim JW
Asian Pac J Cancer Prev; 2014; 15(5):2341-4. PubMed ID: 24716981
[TBL] [Abstract][Full Text] [Related]
20. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma: Description of an Extraordinary Case.
Juhlin CC; Höög A
Int J Surg Pathol; 2019 Sep; 27(6):658-663. PubMed ID: 30931661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]